We assessed the impact of the 2023/2024 COVID-19 vaccination campaign in Italy by estimating the number of averted COVID-19 severe cases (i.e. COVID-19 associated hospitalisations or deaths) between October 2023 and March 2024, in those aged ≥60 years. We estimated that 565 (95 % CI: 497-625) cases, corresponding to 2.1 % (95 % CI: 1.8-2.3) of the expected cases without a vaccination campaign, were averted. We simulated three vaccination coverage scenarios: 50 %, 75 %, 90 % (versus the observed 10.7 %), finding that 9.7 % (95 % CI: 8.5-10.7); 14.5 % (95 % CI: 12.8-16.1); and 17.4 % (95 % CI: 15.3-19.3) of the expected cases would have been averted, respectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2024.126375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding and overcoming geographical barriers for scaling up dog vaccinations against rabies.
Sci Rep
December 2024
Department of Mathematics, Manchester University, Manchester, UK.
Rabies causes 59,000 human deaths annually in over 150 countries. Mass dog vaccination (MDV) is key to controlling dog rabies, requiring 70% coverage in the susceptible dog population to eliminate rabies deaths. MDV campaigns must achieve geographical homogeneity of coverage.
View Article and Find Full Text PDFCurrent state of APPE-readiness assessments in schools or colleges of pharmacy.
Curr Pharm Teach Learn
December 2024
Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, 410 North 12th Street, Richmond, VA 23298, United States of America. Electronic address:
Objective: To determine components and assessments included in Advanced Pharmacy Practice Experience (APPE) readiness plans in United States Doctor of Pharmacy (PharmD) programs.
Methods: An electronic survey was emailed to the American Association of Colleges of Pharmacy Laboratory Instructors Special Interest Group. Survey items included demographic information about the program, APPE-readiness plan implementation status and components.
Impact of COVID-19 Vaccination in Thailand: Averted Deaths and Severe Infections Across Age Groups.
Trop Med Infect Dis
November 2024
Biophysics Group, Department of Physics, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
The COVID-19 pandemic has underscored the pivotal role of vaccines in mitigating the devastating impact of the virus. In Thailand, the vaccination campaign against SARS-CoV-2 began on 28 February 2021, initially prioritizing healthcare professionals before expanding into a nationwide effort on 7 June 2021. This study employs a mathematical model of COVID-19 transmission with vaccination to analyze the impact of Thailand's COVID-19 vaccination program from 1 March 2021 to 31 December 2022.
View Article and Find Full Text PDFSARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study.
Infect Dis Rep
November 2024
Health & Technology Research Center, Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Av. D. João II, Lote 4.69.01, Parque das Nações, 1990-096 Lisboa, Portugal.
Background/objectives: The COVID-19 pandemic has revolutionized vaccine production and compelled a massive global vaccination campaign. This study aimed to estimate the positivity and levels of SARS-CoV-2 IgG antibodies acquired due to vaccination and infection in the academic population of a Portuguese university.
Methods: Blood samples were collected and analyzed through the ELISA methodology, and statistical analysis was performed.
The Impact of HPV Vaccination on Cervical Cancer in adolescent females: A narrative review.
J Family Med Prim Care
November 2024
Department of Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
To effectively prevent cervical cancer, a leading cause of global morbidity and mortality among women, widespread adoption of the HPV vaccine has a well-established link to human papillomavirus (HPV) infection. HPV vaccine must be the vaccine's effectiveness in reducing HPV infections, and subsequent cervical lesions have been extensively demonstrated, marking a pivotal milestone in public health. Important research highlights the vaccine's safety profile, allaying worries and promoting trust in its application.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!